In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Several CRISPR-Cas9 orthologues have been used for genome editing. Here, we present the smallest Cas9 orthologue characterized to date, derived from Campylobacter jejuni (CjCas9), for efficient genome editing in vivo . After determining protospacer-adjacent motif (PAM) sequences and optimizing single-guide RNA (sgRNA) length, we package the CjCas9 gene, its sgRNA sequence, and a marker gene in an all-in-one adeno-associated virus (AAV) vector and produce the resulting virus at a high titer. CjCas9 is highly specific, cleaving only a limited number of sites in the human or mouse genome. CjCas9, delivered via AAV, induces targeted mutations at high frequencies in mouse muscle cells or retinal pigment epithelium (RPE) cells. Furthermore, CjCas9 targeted to the Vegfa or Hif1a gene in RPE cells reduces the size of laser-induced choroidal neovascularization, suggesting that in vivo genome editing with CjCas9 is a new option for the treatment of age-related macular degeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Smaller genome editing proteins, such as the S. aureus Cas9, C. jejuni Cas9 and newly identified CRISPR-Cas enzymes, may circumvent this issue 23,61-65 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The downregulation was linked to a decrease in spot size on morphology of the laser-induced choroidal neovascularization (wet AMD model) but not on retinal function measured by electroretinogram (ERG) [221].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [221]
The cited source says what the claim attributes to it.
In the citing paper
“Fonfara et al. previously reported the optimal in vitro PAM site for CjCas9 to be 5′-NNNNACA”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In February 2017, Kim et al. presented efficient in vivo genome editing using the smallest Cas9 orthologue (2.95 kb) that has been characterized as of February 2017: Campylobacter jejuni (CjCas9) [72].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
The cited source says what the claim attributes to it.
In the citing paper
“In February 2017, Kim et al. presented efficient in vivo genome editing using the smallest Cas9 orthologue (2.95 kb) that has been characterized as of February 2017: Campylobacter jejuni (CjCas9) [72].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [72]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
Self-citationRNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
Self-citationStructural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease
Anders, C., Niewoehner, O., Duerst, A., & Jinek, M. (2014) · Nature · doi:10.1038/nature13579 · Cited by 1,323
Cited by
Items 201–300 of 730
Tariq, A., Mushtaq, M., Yaqoob, H., Bhat, B. A., Zargar, S. M., Raza, A., Ali, S., Charagh, S., Mubarik, M. S., Zaman, Q. U., et al. (2023) · GM Crops & Food · doi:10.1080/21645698.2023.2219111 · Cited by 45
Wu, Y. C., Xu, W., Wang, F., Zhao, S., Feng, F., Song, J., Zhang, C., & Yang, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00379 · Cited by 46
Khan, I., Khan, S., Zhang, Y., Zhou, J., Akhoundian, M., & Jan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06375-0 · Cited by 47
Wheat genome editing expedited by efficient transformation techniques: Progress and perspectives
Wang, K., Riaz, B., & Ye, X. (2017) · The Crop Journal · doi:10.1016/j.cj.2017.09.009 · Cited by 47
Systemic Cytokines in Retinopathy of Prematurity
Wu, P., Fu, Y.-K., Lien, R., Chiang, M., Lee, C., Chen, H., Hsueh, Y., Chen, K., Wang, N., Liu, L., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020291 · Cited by 47
Kim, D., Kang, B., & Kim, J. (2021) · Nature Protocols · doi:10.1038/s41596-020-00453-6 · Cited by 46
Self-citationPaving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 45
Allele-specific genome targeting in the development of precision medicine
Wu, J., Tang, B., & Tang, Y. (2020) · Theranostics · doi:10.7150/thno.43298 · Cited by 45
Prime Editing: An All-Rounder for Genome Editing
Lu, C., Kuang, J., Shao, T., Xie, S., Li, M., Zhu, L., & Zhu, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179862 · Cited by 48
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy
Chen, C., Wang, Z., & Qin, Y. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00457-4 · Cited by 49
Alariqi, M., Ramadan, M., Yu, L., Hui, F., Hussain, A., Zhou, X., Yu, Y., Zhang, X., & Jin, S. (2025) · Advanced Science · doi:10.1002/advs.202416331 · Cited by 51
Therapeutic genome editing in cardiovascular diseases
Nishiga, M., Qi, L. S., & Wu, J. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.003 · Cited by 44
Wide Horizons of CRISPR-Cas-Derived Technologies for Basic Biology, Agriculture, and Medicine
Molla, K. A., Karmakar, S., & Islam, T. (2020) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-0716-0616-2_1 · Cited by 61
Engineered Campylobacter jejuni Cas9 variant with enhanced activity and broader targeting range
Nakagawa, R., Ishiguro, S., Okazaki, S., Mori, H., Tanaka, M., Aburatani, H., Yachie, N., Nishimasu, H., & Nureki, O. (2022) · Communications Biology · doi:10.1038/s42003-022-03149-7 · Cited by 44
Genome-editing strategies for treating human retinal degenerations
Quinn, J., Musa, A., Kantor, A., McClements, M. E., Cehajic-Kapetanovic, J., MacLaren, R. E., & Xue, K. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.231 · Cited by 41
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S., & Blancafort, P. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.009 · Cited by 45
Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles
Ageely, E. A., Chilamkurthy, R., Jana, S. K., Abdullahu, L., O’Reilly, D., Jensik, P. J., Damha, M. J., & Gagnon, K. T. (2021) · Nature Communications · doi:10.1038/s41467-021-26989-z · Cited by 42
The Mechanisms of Genome Editing Technologies in Crop Plants
Ahmad, Y., Haider, S., Iqbal, J., Abbasi, B. A., Yaseen, T., & Mahmood, T. (2022) · Springer eBooks · doi:10.1007/978-3-030-96925-7_13 · Cited by 46
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
Evolution-guided protein design of IscB for persistent epigenome editing in vivo
Kannan, S., Altae-Tran, H., Zhu, S., Xu, P., Strebinger, D., Oshiro, R., Faure, G., Moeller, L., Pham, J., Mears, K. S., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02655-3 · Cited by 48
Erwood, S., Laselva, O., Bily, T. M. I., Brewer, R. A., Rutherford, A. H., Bear, C. E., & Ivakine, E. A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.002 · Cited by 41
Tickner, Z. J., & Farzan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14060554 · Cited by 45
A most formidable arsenal: genetic technologies for building a better mouse
Clark, J. F., Dinsmore, C. J., & Soriano, P. M. (2020) · Genes & Development · doi:10.1101/gad.342089.120 · Cited by 45
Sanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 42
CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing
Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.013 · Cited by 40
Closely related type II-C Cas9 orthologs recognize diverse PAMs
Wei, J., Hou, L., Liu, J., Wang, Z., Gao, S., Qi, T., Gao, S., Sun, S., & Wang, Y. (2022) · eLife · doi:10.7554/elife.77825 · Cited by 42
Compact Cas9d and HEARO enzymes for genome editing discovered from uncultivated microbes
Goltsman, D. S. A., Alexander, L. M., Lin, J., Ocampo, R. F., Freeman, B., Lamothe, R. C., Rivas, A. P., Temoche-Diaz, M. M., Chadha, S., Nordenfelt, N. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35257-7 · Cited by 39
Editor's cut: DNA cleavage by CRISPR RNA-guided nucleases Cas9 and Cas12a
Swartjes, T., Staals, R. H. J., & John van der, O. O. S. T. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190563 · Cited by 39
On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
Korablev, A. N., Lukyanchikova, V., Serova, I. A., & Баттулин, Н. Р. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103604 · Cited by 40
CRISPR-based VEGF suppression using paired guide RNAs for treatment of choroidal neovascularization
Chung, S. H., Sin, T.-N., Dang, B., Ngo, T., Lo, T., Lent-Schochet, D., Meleppat, R. K., Zawadzki, R. J., & Yiu, G. (2022) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2022.04.015 · Cited by 37
Holmgaard, A. B., Askou, A. L., Jensen, E. G., Alsing, S., Bak, R. O., Mikkelsen, J. G., & Corydon, T. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.032 · Cited by 36
Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
Wu, X., Ma, W., Mei, C., Chen, X., Yao, Y., Liu, Y., Qin, X., & Yuan, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01603-0 · Cited by 38
Enhancing site-specific DNA integration by a Cas9 nuclease fused with a DNA donor-binding domain
Ma, S., Wang, X., Hu, Y., Lv, J., Liu, C., Liao, K., Guo, X., Wang, D., Lin, Y., & Rong, Z. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa779 · Cited by 41
Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System
Meneghini, V., Peviani, M., Luciani, M., Zambonini, G., & Gritti, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.644319 · Cited by 41
Progresses, Challenges, and Prospects of CRISPR/Cas9 Gene-Editing in Glioma Studies
Kang, X., Wang, Y., Liu, P., Huang, B., Zhou, B., Lu, S., Geng, W., & Tang, H. (2023) · Cancers · doi:10.3390/cancers15020396 · Cited by 39
CRISPR/Cas-Mediated Genome Engineering in Plants: Application and Prospectives
Mishra, S., Nayak, S., Tuteja, N., Poosapati, S., Swain, D. M., & Sahoo, R. K. (2024) · Plants · doi:10.3390/plants13141884 · Cited by 39
Harnessing the evolving CRISPR/Cas9 for precision oncology
Li, T., Li, S., Kang, Y., Zhou, J., & Yi, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05570-4 · Cited by 39
Emerging Approaches for Spatiotemporal Control of Targeted Genome with Inducible CRISPR-Cas9
Nihongaki, Y., Otabe, T., & Sato, M. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04757 · Cited by 39
Chung, S. H., Mollhoff, I. N., Nguyen, U. T. T., Nguyen, A. B., Stucka, N., Tieu, E., Manna, S. K., Meleppat, R. K., Zhang, P., Nguyen, E. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.006 · Cited by 37
Engineering a PAM-flexible SpdCas9 variant as a universal gene repressor
Wang, J., Teng, Y., Zhang, R., Wu, Y., Lou, L., Zou, Y., Li, M., Xie, Z., & Yan, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-27290-9 · Cited by 36
Comparison of CRISPR/Cas Endonucleases for in vivo Retinal Gene Editing
Li, F., Wing, K., Wang, J.-H., Luu, C. D., Bender, J. A., Chen, J., Wang, Q., Lu, Q., Nguyen Tran, M. T., Young, K. M., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.570917 · Cited by 34
Engineering CRISPR guide RNA riboswitches for in vivo applications
Galizi, R., & Jaramillo, A. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.08.007 · Cited by 36
Lohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Harnessing the natural diversity and in vitro evolution of Cas9 to expand the genome editing toolbox
Karvelis, T., Gasiūnas, G., & Šikšnys, V. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.05.009 · Cited by 34
Revolution in Gene Medicine Therapy and Genome Surgery
Jiang, D. J., Xu, C. L., & Tsang, S. H. (2018) · Genes · doi:10.3390/genes9120575 · Cited by 34
Luo, Z., Gao, M., Huang, N., Wang, X., Yang, Z., Yang, H., Huang, Z., & Feng, W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1229-5 · Cited by 36
Applications of CRISPR/Cas9 in the Mammalian Central Nervous System.
Savell, K. E., & Day, J. J. (2017) · PubMed Central · Cited by 39
CRISPR Interference–Potential Application in Retinal Disease
Peddle, C. F., Fry, L. E., McClements, M. E., & MacLaren, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072329 · Cited by 34
Germline engineering of the chicken genome using CRISPR/Cas9 by in vivo transfection of PGCs
Challagulla, A., Jenkins, K. A., O’Neil, T. E., Morris, K. R., Wise, T. G., Tizard, M. L., Bean, A. G. D., Schat, K. A., & Doran, T. J. (2020) · Animal Biotechnology · doi:10.1080/10495398.2020.1789869 · Cited by 36
Chen, G., Wei, T., Yang, H., Li, G., & Li, H. (2022) · Cells · doi:10.3390/cells11192964 · Cited by 36
Diverse Class 2 CRISPR-Cas Effector Proteins for Genome Engineering Applications
Pyzocha, N., & Chen, S. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00800 · Cited by 36
In Vivo Applications of CRISPR-Based Genome Editing in the Retina
Yu, W., & Wu, Z. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00053 · Cited by 33
Therapeutic strategies for autism: targeting three levels of the central dogma of molecular biology
Hong, D., & Iakoucheva, L. M. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02356-y · Cited by 36
Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins
Hwang, S., & Maxwell, K. L. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168041 · Cited by 32
Genome editing in rice mediated by miniature size Cas nuclease SpCas12f
Sukegawa, S., Nureki, O., Toki, S., & Saika, H. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1138843 · Cited by 33
Advances in Alpha-1 Antitrypsin Gene Therapy
Lőrincz, R., & Curiel, D. T. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0159ps · Cited by 33
The Off-Targets of Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing
Vicente, M. M., Chaves‐Ferreira, M., Jorge, J. M. P., Proença, J. T., & Barreto, V. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.718466 · Cited by 42
Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas
Yang, Y.-C., & Yang, H. (2021) · Viruses · doi:10.3390/v14010004 · Cited by 33
Compact Cje3Cas9 for Efficient In Vivo Genome Editing and Adenine Base Editing
Chen, S., Liu, Z., Xie, W., Yu, H., Lai, L., & Li, Z. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0143 · Cited by 31
Gene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
“149 be delivered into a cell in 3 different forms—DNA plasmid, mRNA, and protein.”
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A. P., Kachanov, A., Brezgin, S. A., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 31
Ibuki, M., Shoda, C., Miwa, Y., Ishida, A., Tsubota, K., & Kurihara, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00174 · Cited by 31
CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy
Lim, K. R. Q., Nguyen, Q., Dzierlega, K., Huang, Y., & Yokota, T. (2020) · Genes · doi:10.3390/genes11030342 · Cited by 30
Botto, C., Dalkara, D., & El-Amraoui, A. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.737632 · Cited by 32
Yin, J., Fang, K., Gao, Y., Ou, L., Yuan, S., Xin, C., Wu, W., Wu, W., Hong, J., Yang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35640-4 · Cited by 32
Molecular basis for the PAM expansion and fidelity enhancement of an evolved Cas9 nuclease
Chen, W., Zhang, H., Zhang, Y., Wang, Y., Gan, J., & Ji, Q. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000496 · Cited by 31
Mini-PE, a prime editor with compact Cas9 and truncated reverse transcriptase
Lan, T., Chen, H., Tang, C., Wei, Y., Liu, Y., Zhou, J., Zhuang, Z., Zhang, Q., Chen, M., Zhou, X., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.08.018 · Cited by 30
Hwang, J., & Yokota, T. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.5 · Cited by 31
Yoon, A. R., Jung, B., Choi, E., Chung, E., Hong, J., Kim, J., Koo, T., & Yun, C. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.003 · Cited by 29
Self-citationVersatile and efficient in vivo genome editing with compact Streptococcus pasteurianus Cas9
Liu, Z., Chen, S., Xie, W., Song, Y., Li, J., Lai, L., & Li, Z. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.013 · Cited by 29
Genome editing with type II‐C CRISPR‐Cas9 systems from Neisseria meningitidis in rice
Xu, R., Qin, R., Xie, H., Li, J., Liu, X., Zhu, M., Sun, Y., Yu, Y., Lu, P., & Wei, P. (2021) · Plant Biotechnology Journal · doi:10.1111/pbi.13716 · Cited by 29
Husaini, C. U. N., Roslan, R., Ramzi, A. B., Luthfi, A. A. I., Tan, J. P., Lim, S. S., Ding, G., Jahim, J. M., & Abdul, P. M. (2023) · International Journal of Hydrogen Energy · doi:10.1016/j.ijhydene.2023.03.162 · Cited by 29
Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications
Zhou, L., & Yao, S. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00115-5 · Cited by 33
Liu, X., Huang, K., Zhang, F., Huang, G., Wang, L., Wu, G., Ren, H., Yang, G., & Lin, Z. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02614-1 · Cited by 30
Rabinowitz, R., Almog, S., Darnell, R., & Offen, D. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00851 · Cited by 30
Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency
García‐Tuñón, I., Alonso-Pérez, V., Vuelta, E., Pérez‐Ramos, S., Herrero, M., Méndez, L., Hernández-Sánchez, J. M., Martín‐Izquierdo, M., Saldaña, R., Sevilla, J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0216674 · Cited by 28
The MyLO CRISPR-Cas9 toolkit: a markerless yeast localization and overexpression CRISPR-Cas9 toolkit
Bean, B. D. M., Whiteway, M. S., & Martin, V. J. J. (2022) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkac154 · Cited by 28
Progress in the application of CRISPR: From gene to base editing
Wu, W., Yang, Y., & Lei, H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21537 · Cited by 34
Gene editing prospects for treating inherited retinal diseases
Benati, D., Patrizi, C., & Recchia, A. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106473 · Cited by 30
Exploring the potential of cell-derived vesicles for transient delivery of gene editing payloads
Leandro, K., Rufino‐Ramos, D., Breyne, K., Ianni, E. D., Lopes, S., Nobre, R. J., Kleinstiver, B. P., Perdigão, P. R. L., Breakefield, X. O., & de Almeida, L. P. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115346 · Cited by 28
Phaneuf, C. R., Seamon, K. J., Eckles, T., Sinha, A., Schoeniger, J. S., Harmon, B., Meagher, R. J., Abhyankar, V. V., & Koh, C. (2019) · Analytical Methods · doi:10.1039/c8ay02726a · Cited by 28
Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing
Chae, S.-Y., Jeong, E., Kang, S., Yim, Y., Kim, J., & Min, D. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.035 · Cited by 28
Self-citationLi, J., Wu, P., Cao, Z., Huang, G., Lu, Z., Yan, J., Zhang, H., Zhou, Y., Liu, R., Chen, H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113765 · Cited by 26
Gene-based therapeutics for acquired retinal disease: opportunities and progress
Tan, T.-E., Fenner, B. J., Barathi, V. A., Tun, S. B. B., Wey, Y. S., Tsai, A. S. H., Su, X., Lee, S. Y., Cheung, C. M. G., Wong, T. Y., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.795010 · Cited by 26
Transplacental Gene Delivery (TPGD) as a Noninvasive Tool for Fetal Gene Manipulation in Mice
Nakamura, S., Watanabe, S., Ando, N., Ishihara, M., & Sato, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235926 · Cited by 27
Targeting vascular endothelial growth factor using retinal gene therapy
Chung, S. H., Frick, S. L., & Yiu, G. C. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4417 · Cited by 28
PpCas9 from Pasteurella pneumotropica — a compact Type II-C Cas9 ortholog active in human cells
Fedorova, I., Vasileva, A., Selkova, P., Abramova, M., Arseniev, A., Pobegalov, G., Kazalov, M., Musharova, O. S., Goryanin, I. I., Artamonova, D., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa998 · Cited by 27
Smith, R. H., Chen, Y.-C., Seifuddin, F., Hupalo, D. N., Alba, C., Reger, R. N., Tian, X., Araki, D., Dalgard, C. L., Childs, R. W., et al. (2020) · Genes · doi:10.3390/genes11121501 · Cited by 29
Basic Principles and Clinical Applications of CRISPR-Based Genome Editing
Lim, J. M., & Kim, S. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.2.105 · Cited by 28
Self-citationIjaz, M., Khan, F. S. A., Zaki, H. E. M., Khan, M. M., Radwan, K. S. A., Jiang, Y., Jiahui, Q., Ahmed, T., Shahid, M. S., Luo, J., et al. (2023) · Plants · doi:10.3390/plants12091911 · Cited by 29
Bigini, F., Hyeon, L. S., Sun, Y. J., Sun, Y., & Mahajan, V. B. (2023) · Vision Research · doi:10.1016/j.visres.2023.108317 · Cited by 31
CoCas9 is a compact nuclease from the human microbiome for efficient and precise genome editing
Pedrazzoli, E., Demozzi, M., Visentin, E., Ciciani, M., Bonuzzi, I., Pezzè, L., Lucchetta, L., Maule, G., Amistadi, S., Esposito, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47800-9 · Cited by 28
Innovations in CRISPR technology
Brooks, A. K., & Gaj, T. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.03.007 · Cited by 28
Šikrová, D., Cadar, V. A., Ariyürek, Y., Laros, J. F. J., Balog, J., & van der Maarel, S. M. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.020 · Cited by 27
CRISPR/Cas therapeutic strategies for autosomal dominant disorders
Caruso, S. M., Quinn, P. M. J., da Costa, B. L., & Tsang, S. H. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158287 · Cited by 29
Dai, L., Wu, Z., Şahin, O., Zhao, S., Yu, E. W., & Zhang, Q. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2415823121 · Cited by 28
Gene Therapy in Diabetic Retinopathy and Diabetic Macular Edema: An Update
Odio-Herrera, M., Loaiza, G. O., & Wu, L. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093205 · Cited by 25
Murugan, K., Suresh, S. K., Seetharam, A. S., Severin, A. J., & Sashital, D. G. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab163 · Cited by 26
CRISPR-Cas9 and beyond: what’s next in plant genome engineering
Zess, E. K., & Begemann, M. B. (2021) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/s11627-021-10185-1 · Cited by 28
Recent Advances in CRISPR/Cas9-Based Genome Editing Tools for Cardiac Diseases
Schreurs, J., Sacchetto, C., Colpaert, R. M. W., Vitiello, L., Rampazzo, A., & Calore, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010985 · Cited by 26
Metadata
- Authors
- Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., Kim, J. H., Kim, J. H., & Kim, J.-S.
- Affiliations
- Institute for Basic Science (KR)
- Seoul National University (KR)
- ToolGen (South Korea) (KR)
- Corresponding author
- Kim, Jeong Hun
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-21
- Volume
- 8
- Issue
- 1
- Pages
- 14500-14500
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5473640
- OpenAlex
- W2590764628
- Cited by
- 715
- References
- 38
- Citations by year
- 2026: 24 · 2025: 68 · 2024: 68 · 2023: 81 · 2022: 114 · 2021: 94 · 2020: 87 · 2019: 77 · 2018: 66 · 2017: 36
- FWCI
- 29.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- National Research Foundation (NRF-2015M3A9E6028949)
- Ministry of Science, ICT and Future Planning (NRF-2015M3A9E6028949, IBS-R021-D1, 2015M3A9E6028949)
- Korea Health Industry Development Institute (HI16C0426)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- in vivo gene editing, adeno-associated virus vectors, single guide RNA, protospacer adjacent motif, retinal pigment epithelium, choroidal neovascularization, age-related macular degeneration, VEGF-A, HIF1A, targeted mutagenesis
- MeSH terms
- Gene Editing, Dependovirus, Animals, Bacterial Proteins, Cells, Cultured, Endonucleases, Humans, Male, Mice, Inbred C57BL, Campylobacter jejuni, Choroidal Neovascularization, Vascular Endothelial Growth Factor A, Retinal Pigment Epithelium, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.